Radar · Infectious Diseases in Canada
Best Infectious Diseases Companies in Canada
The 85 best Infectious Diseases companies in Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Methylgene.
By Rohit KhannaTrends & Stories
85companies tracked
$565.2Mdisclosed funding
0unicorns
38have raised
FLIAR INTELLIGENCE · INFECTIOUS DISEASES × CANADA
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
59%cloud-native stacks
2025funding peak (by rounds)
1unicorns
2014median founding year
65kcombined LinkedIn audience
38%of audience held by top 3
1companies hiring publicly (12 mo)
Ranked: Best Infectious Diseases companies in Canada
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Stage | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Methylgene Developer of therapeutics for cancer and infectious diseases | $62M | 163 mo ago | — | Charles Grubsztajn CEO | — | Acquired | — | 412 patents Small-molecule kinase and HDAC inhibitor therapeutics for oncology | — |
| 2 | Xagenic Provider of point-of-care molecular diagnostics for infectious diseases | $59M | 131 mo ago | 45 | — | — | Series C | — | 50 patents Electrochemical biosensor platforms and precision current‑mode DACs for point‑of‑care diagnostics | — |
| 3 | Medicago Developer of vaccines to treat pandemic and seasonal influenza | $50M | 176 mo ago | 600 | Toshifumi Tada CEO | — | Acquired | — | 711 patents Plant-based virus-like particle production for influenza and other viral vaccines | — |
| 4 | Radiant Biotherapeutics Developer of therapeutics for cancer, auto-immune and infectious diseases 37Patents top 33%Funding top 34%Moat top 38%Innovation top 40% All 9 signals ▾Patentstop 33% Fundingtop 34% Moattop 38% Innovationtop 40% Techtop 41% Growthbottom 47% Globalbottom 40% Marketbottom 26% Newsbottom 18% Patents: 38 patents matched (strict assignee match) · 38 filings since 2022 vs 0 in 2017-21 Funding: Raised $43.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $43M | 21 mo ago | 11 | — | WordPress Block EditorWordPressMySQL+16 | Series A | — | 38 patents Engineered multibody protein therapeutics targeting TNF receptors and multivalent cytokine modulation | — |
| 5 | Qvella Developer of a platform aimed to provide a more accurate and faster diagnosis of bacteria identification | $40M | 102 mo ago | 101 | — | — | Deadpooled | — | 85 patents Rapid microbial diagnostics: cell separation, microcolony classification, and antibiotic susceptibility testing. | — |
| 6 | SQI Diagnostics Developer of multiplexed tests and automated systems for biological testing. | $37M | 42 mo ago | 70 | — | — | Public | — | 75 patents High‑throughput multiplex microarray immunoassay analysis and quantification platforms | — |
| 7 | SaNOtize Developer of a nitric oxide-based solution to treat infections | $34M | 45 mo ago | 15 | Gilly Regev Co-Founder | WordPressMySQLPHP+20 | Series B | — | — | — |
| 8 | Spectral Develops theranostic solutions for sepsis | $30M | 43 mo ago | 32 | Chris Seto Chief Executive Officer | WordPressMySQLPHP+19 | Public | — | — | — |
| 9 | Qu Biologics Developing Site Specific Immunomodulators that aim to reboot the body's immune system to treat cancer and… | $30M | 51 mo ago | 22 | — | WordPressMySQLPHP+20 | Series C | — | 80 patents Innate immune modulation for cell therapies, anti‑inflammatory and antimicrobial biologics | — |
| 10 | Sunshine Biopharma Developer of antiviral and anticancer drugs | $28M | 37 mo ago | 46 | — | WordPressMySQLPHP+15 | Public | — | 2 patents Patents concentrated in health & consumer products | — |
| 11 | Inimex Pharmaceuticals Develops Innate Defense Regulator drugs for infections and tissue injury | $28M | 216 mo ago | — | Brett Finlay Co-Founder | — | Deadpooled | — | 36 patents Peptide-based therapeutics modulating innate immunity for infection and immune disorder treatment | — |
| 12 | Revive Therapeutics Developer of therapeutics to treat rare and infectious diseases 27Product top 24%Moat top 32%Funding top 36%Patents top 42% All 10 signals ▾Producttop 24% Moattop 32% Fundingtop 36% Patentstop 42% Innovationtop 44% Growthtop 48% Techbottom 48% Newsbottom 43% Globalbottom 31% Marketbottom 16% Product: 2 distinct product lines · Company stage: Public Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $17M | 10 mo ago | 3 | — | WordPressMySQLPHP+16 | Public | 3 signals ▼57% Funding | 24 patents Repurposing bucillamine and psilocybin for CNS injury, stroke, migraine, and infections | — |
| 13 | Appili Therapeutics Developer of drugs to treat infectious diseases 32Funding top 31%Product top 32%Tech top 40%Moat top 42% All 10 signals ▾Fundingtop 31% Producttop 32% Techtop 40% Moattop 42% Newstop 49% Patentstop 50% Globalbottom 48% Growthbottom 47% Innovationbottom 44% Marketbottom 27% Funding: Raised $15.5M across 18 rounds · 18 rounds over 10 yrs (1.8/yr) Product: 3 distinct product lines · Company stage: Acquired rank vs industry peers · Fliar Intelligence Index 32/100 | $16M | 6 mo ago | 9 | — | WordPressMySQLPHP+24 | Acquired | 5 signals ▼67% Earnings · Funding | 15 patents Oral metronidazole formulations and antifungal compositions for Candida auris treatment | — |
| 14 | Bionxt Developer of drug formulations and delivery systems for various diseases 37News top 36%Funding top 38%Partners top 40%Patents top 46% All 11 signals ▾Newstop 36% Fundingtop 38% Partnerstop 40% Patentstop 46% Growthtop 47% Talenttop 49% Moatbottom 49% Innovationbottom 46% Techbottom 43% Marketbottom 39% Globalbottom 38% News: 9 BI events in 12 mo (of 28 tracked, 7 types) · -36% YoY Funding: Raised $12.6M across 11 rounds · 11 rounds over 4 yrs (2.8/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $13M | 15 mo ago | 25 | Hugh Rogers CEO | WordPressMySQLPHP+20 | Public | 7 signals ▼56% Leadership · Contracts · Funding | 7 patents Psilocin-derived therapeutics and enteric drug delivery formulations for oral pharmaceuticals | 1 partnership |
| 15 | Virica Biotech Developer of viral sensitizer technology therapeutics to treat viral infections | $12M | 25 mo ago | 29 | Jean Diallo Founder & CEO | WordPressMySQLPHP+31 | Series A | — | 4 patents Enhancing viral vector production using kinase inhibitor-based bioprocess methods. | 1 launch · 1 partnership |
| 16 | Chipcare Develops a hand-held blood test from a single drop of blood | $11M | 115 mo ago | 10 | — | — | Deadpooled | — | 24 patents Multiplexed bead-based immunoassays and optical cell detection platforms using fluidic chips | — |
| 17 | Fio Point-of-care digital diagnostic integrated with cloud information services for infectious diseases | $11M | 114 mo ago | 40 | Michael Greenberg Chairman and Chief Executive Officer | Cart FunctionalitySquarespace CommerceSquarespace+23 | Series B | — | 190 patents Point‑of‑care rapid immunoassay diagnostics with biomarker analytics and cloud data integration | — |
| 18 | Arbutus Bio Developer of nucleic acid-based therapeutics | $10M | 54 mo ago | 2 | — | DrupalPHPAmazon Web Services+20 | Public | — | — | — |
| 19 | Providence Therapeutics Developer of mRNA-based therapeutics for cancer and covid-19 treatment 55Patents top 24%Moat top 32%Innovation top 35%Growth top 35% All 11 signals ▾Patentstop 24% Moattop 32% Innovationtop 35% Growthtop 35% Talenttop 38% Fundingtop 43% Marketbottom 49% Newsbottom 45% Globalbottom 43% Partnersbottom 35% Techbottom 29% Patents: 54 patents matched (strict assignee match) · 54 filings since 2022 vs 0 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 54 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $9M | 13 mo ago | 68 | Eric Marcusson Co-Founder | JoomlaPHPThree.js+15 | Series A | — | 54 patents Lipid nanoparticle formulations for nucleic acid vaccine delivery and infectious disease therapeutics | — |
| 20 | Noze Developer of a breath-based diagnostic platform to detect disease markers noninvasively | $7M | 22 mo ago | 54 | Ashok Masilamani Chief Technology Officer and Founder | WebflowGSAPjsDelivr+6 | Seed | — | — | — |
| 21 | MedMira Diagnostic devices for rapid multiplex immuno-testing | $6M | 54 mo ago | 26 | — | — | Public | 3 signals ▼79% Announcements | 32 patents Patents concentrated in computing, sensing & instrumentation | 1 launch |
| 22 | Gladius Pharma Canadian, early stage biopharma developing modified beta-lactam compounds for MDR gram-negative infections | $3M | 132 mo ago | 6 | Michael Atkin President & CEO | — | Deadpooled | — | — | — |
| 23 | FluroTech Provider of fluorescence spectroscopy-based technology solutions | $3M | 25 mo ago | 18 | Danny Longa Co-Founder & CEO | — | Public | — | — | — |
| 24 | Cytophage Developer of bacteriophages for the treatment of bacterial infections 32Growth top 35%Funding top 45%Talent top 45%Tech bottom 37% All 6 signals ▾Growthtop 35% Fundingtop 45% Talenttop 45% Techbottom 37% Globalbottom 36% Marketbottom 27% Growth: Fresh capital in last 24 mo Funding: Raised $1.8M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $2M | 8 mo ago | 16 | Steven Theriault Chief Executive Officer | WordPressMySQLPHP+21 | Public | — | — | — |
| 25 | Lactiga Developer of immunotherapies to treat infectious diseases | $2M | 16 mo ago | 5 | Viraj Mane Co-Founder | — | Seed | — | 8 patents Polyclonal antibody therapeutics for RSV and oral breast‑milk‑derived immunoglobulin delivery | — |
| 26 | Micropharma Develops biotherapeutics for metabolic diseases | $851K | 160 mo ago | — | Satya Prakash Founder | — | Acqui-Hired | — | 25 patents Probiotic therapeutic formulations and ingestible oral drug delivery devices | — |
| 27 | Biocure Technology Developer and manufacturer of bio-similar products | $849K | 67 mo ago | — | Sang Lee Founder & CEO | — | Public | — | — | — |
| 28 | T.A.Z. Corporation Developer of small molecule for the treatment of antimicrobial resistant infections | $813K | 101 mo ago | — | Keith Micetich CEO | — | Seed | — | — | — |
| 29 | Ondine Biomedical Developer of anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections | $798K | 16 mo ago | 38 | Carolyn Cross Founder & CEO | — | Public | — | — | 1 award |
| 30 | Ostia Sciences Developer of microbes for fighting infectious diseases and enhancing immune function | $740K | 11 mo ago | — | Michael Glogauer Co-Founder | — | Seed | — | — | — |
| 31 | DeNovaMed UK-based, early-stage biotech developing lipid metabolism-targeted small molecules for DR bacterial infections | $500K | 166 mo ago | 11 | Christopher McMaster CEO | — | Seed | — | 33 patents Novel thiophene-based antibacterial compounds for topical infection treatments | — |
| 32 | StokedBio Developer of therapeutics based on AI technology 45Talent top 28%AI top 45%Funding top 46%Market bottom 37% All 5 signals ▾Talenttop 28% AItop 45% Fundingtop 46% Marketbottom 37% Globalbottom 29% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 45/100 | $366K | 1 mo ago | — | Chris Sinclair Co-Founder | — | Seed | — | — | — |
| 33 | Sairiyo Therapeutics Developer of therapeutic solutions for the treatment of rare diseases | $300K | 35 mo ago | — | Paul Slyke Co-Founder & CSO | — | Acqui-Hired | — | — | — |
| 34 | Fedora Pharma Canadian, early-stage biotech developing beta-lactamase inhibitors as combination therapy for MDR infections… | $200K | 13 mo ago | 5 | Christopher Micetich Founder | — | Seed | — | — | — |
Top 12 Infectious Diseases companies in Canada
#1
Acquired · Halifax, Nova Scotia · founded 2015 · 9 employees$15.5Mraised▾
Acquired · Halifax, Nova Scotia · founded 2015 · 9 employees
Developer of drugs to treat infectious diseases. The company's product API-1503 is a class of 30S ribosome targeting agents for Gram-negative bacterias, API-1501 is a formulation of metronidazole, TI-2307 is a broad spectrum anti-fungal, ATI-1701 is a Tularemia vaccine, and Avigan is a broad-spectrum antiviral and therapeutic for COVID-19.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 31%Product
top 32%Tech
top 40%Moat
top 42%News
top 49%Patents
top 50%Funding: Raised $15.5M across 18 rounds · 18 rounds over 10 yrs (1.8/yr) · Last round Grant (prize money) (Dec 2025)
Product: 3 distinct product lines · Company stage: Acquired
Tech: 34 technologies across 4/8 capability areas · Cloud: Cloudflare · Devops: Nginx
Audience (LinkedIn): 3k LinkedIn followers — 4.6% of this cohort's audience
Funding rounds
- Dec 2025Grant (prize money)$11.7M
- Nov 2025Post IPO$532.7K
- Apr 2025Grant (prize money)$11.7M
- Mar 2025Grant (prize money)$11.7M
Investors
Invest Nova Scotia, United States Air Force Academy, Defense.gov, Atlantic Canada Opportunities Agency, Fujifilm, The Lind Partners
Tech stack
All In One SeoBootstrapCdnjsCloudflareCloudflare Bot ManagementCore-Js
#2
Public · Toronto, Ontario · founded 2012 · 3 employees$16.8Mraised▾
Public · Toronto, Ontario · founded 2012 · 3 employees
Developer of therapeutics to treat rare and infectious diseases. Its lead product Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) helps in treating infectious diseases, including COVID-19, influenza, and others. Also has psilocybin for multiple indications.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Product
top 24%Moat
top 32%Funding
top 36%Patents
top 42%Innovation
top 44%Growth
top 48%Product: 2 distinct product lines · Company stage: Public
Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents
Funding: Raised $16.8M across 11 rounds · 11 rounds over 13 yrs (0.8/yr) · Last round Post IPO (Aug 2025)
Audience (LinkedIn): 1k LinkedIn followers — 2.2% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Aug 2025Post IPO$110.7K
- Apr 2025Post IPO$120.2K
- Jan 2024Post IPO$1.6M
- Jan 2023Post IPO$4.3M
Investors
EMD Financial, Planet Ventures
Tech stack
Apache Http ServerCloudflareCloudflare Bot ManagementDiviGodaddyGoogle Analytics
#3
Series A · Calgary, Alberta · founded 2015 · 68 employees$8.5Mraised▾
Series A · Calgary, Alberta · founded 2015 · 68 employees
Developer of mRNA-based therapeutics for cancer and covid-19 treatment. The company's mRNA vaccines are customized based on the patient's tumor-specific mutations to induce an immune response. It generates strong T-cell responses that aim to kill cancer cells and destroy tumors. Also, developed PTX-COVID19-B and PTX-COVID19-LT for covid-19 treatment.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Patents
top 24%Moat
top 32%Innovation
top 35%Growth
top 35%Talent
top 38%Funding
top 43%Patents: 54 patents matched (strict assignee match) · 54 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 7/10 · IP moat: 54 patents · 10 curated direct competitors tracked
Innovation: 54 patents (top 46% of patent-holders) · 54 filings since 2022 vs 0 in 2017-21
Audience (LinkedIn): 7k LinkedIn followers — 11.3% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2025Conventional Debt$711.6K
- May 2025Series A$711.6K
- Mar 2025Series A$209.8K
- Jan 2025Series A$395.4K
Founders & team
Investors
NGen, Gates, JLABS
Tech stack
Animate.CssApache Http ServerBootstrapBunnyGodaddyGoogle Analytics
#4
Public · Vancouver, British Columbia · founded 2018 · 25 employees$12.6Mraised▾
Public · Vancouver, British Columbia · founded 2018 · 25 employees
Developer of drug formulations and delivery systems for various diseases. The company focuses on developing precision transdermal and oral dissolvable drug delivery formulations, rapid, infectious disease, and oral health screening tests, and clinical evaluation of active pharmaceutical ingredients for neurological applications. The company's product include Vektor a drug formulation for efficient and affordable delivery of approved neurological medications.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
News
top 36%Funding
top 38%Partners
top 40%Patents
top 46%Growth
top 47%Talent
top 49%News: 9 BI events in 12 mo (of 28 tracked, 7 types) · -36% YoY · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding: Raised $12.6M across 11 rounds · 11 rounds over 4 yrs (2.8/yr) · Last round Post IPO (Feb 2025)
Partners: 2 contract events in 12 mo · Named contractor/client in 2 deals
Audience (LinkedIn): 584 LinkedIn followers
Activity (LinkedIn): 1 product launches · 2 partnerships (incl. BioNxt Solutions Inc.) announced in 12 mo
Funding rounds
- Feb 2025Post IPO$1.7M
- Jan 2025Post IPO$138.9K
- Jan 2025Post IPO$620.1K
- Jan 2025Post IPO$288.8K
Founders & team
Investors
Planet Ventures
Tech stack
Advanced Custom FieldsAmazon S3Amazon Web ServicesCookieyesElementorGodaddy
#5
Series A · Toronto, Ontario · founded 2020 · 11 employees$43Mraised▾
Series A · Toronto, Ontario · founded 2020 · 11 employees
Developer of therapeutics for cancer, auto-immune and infectious diseases. It offers multi-valent, multi-specific antibody therapeutics based on antibody engineering platform that targets biological pathways to treat diverse diseases.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Patents
top 33%Funding
top 34%Moat
top 38%Innovation
top 40%Tech
top 41%Growth
bottom 47%Patents: 38 patents matched (strict assignee match) · 38 filings since 2022 vs 0 in 2017-21 · Latest publication 2025
Funding: Raised $43.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Series A (Sep 2024)
Moat: Editorial + unicorn rating 5/10 · IP moat: 38 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 5k LinkedIn followers — 7.2% of this cohort's audience
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · hiring: Senior Director/Vice President, CMC, Senior Director, Program Leadership
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Sep 2024Series A$35M
- Apr 2023Seed$8M
Investors
Gates, Amplitude, abrdn, FACIT, Alexandria, TIAP
Tech stack
AngularCart FunctionalityCore-JsGodaddyGoogle Font ApiHsts
#6
Seed · Hamilton, Ontario · founded 2024$365.5Kraised▾
Seed · Hamilton, Ontario · founded 2024
Developer of therapeutics based on AI technology. It offers AI-based platform for molecular property prediction and molecular design for drug discovery for antibacterial, antifungal, antiviral, and cancer applications.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Talent
top 28%AI
top 45%Funding
top 46%Market
bottom 37%Global
bottom 29%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
AI: Product described with: ai-based
Funding: Raised $366k across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (May 2026)
Audience (LinkedIn): 1k LinkedIn followers — 2.3% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. McMaster) announced in 12 mo
Funding rounds
- May 2026Seed$365.5K
Founders & team
Investors
Ontario Canada
#7
Public · Winnipeg, Manitoba · founded 2019 · 16 employees$1.8Mraised▾
Public · Winnipeg, Manitoba · founded 2019 · 16 employees
Developer of bacteriophages for the treatment of bacterial infections. These phages can be used for treating acne and eczema, internal bacterial infections such as pneumonia, preventing wound infections, and for decontamination of hospital surfaces. The company has developed customized bacteriophages in a combination of natural and genetically modified bacteriophages that target and destroy bacterial organisms found in humans, animals, agricultural crops, on the surfaces in healthcare or food industries.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Growth
top 35%Funding
top 45%Talent
top 45%Tech
bottom 37%Global
bottom 36%Market
bottom 27%Growth: Fresh capital in last 24 mo
Funding: Raised $1.8M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Post IPO (Oct 2025)
Talent: 2 named leaders on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers — 2.9% of this cohort's audience
Funding rounds
- Oct 2025Post IPO$713.5K
- May 2025Post IPO$1.1M
Founders & team
Investors
Innovation Incubator
Tech stack
All In One SeoCore-JsElementorFormidable FormGoogle AnalyticsGoogle Workspace
#8
Seed · Montreal, Quebec · founded 2015 · 54 employees$6.8Mraised▾
Seed · Montreal, Quebec · founded 2015 · 54 employees
Developer of a breath-based diagnostic platform to detect disease markers noninvasively. The platform uses nano-sensor arrays to detect molecular patterns. Proprietary neural models translate these patterns into diagnostic meaning. The platform is designed for semiconductor manufacturing to achieve global reach. It aims to provide earlier detection and faster interventions for better outcomes. The platform has two modes: SpotLight and DeepScan.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 6.7% of this cohort's audience
Funding rounds
- Jul 2024Seed$5M
- Mar 2023Grant (prize money)$1M
Founders & team
Investors
Gates, Beresford Ventures
Tech stack
CloudflareGoogle WorkspaceGsapHstsHttp/3Jquery
#9
Seed · Toronto, Ontario · founded 2020$739.9Kraised▾
Seed · Toronto, Ontario · founded 2020
Developer of microbes for fighting infectious diseases and enhancing immune function. The company offers Salivaricin 10 a phosphorylated antibiotic in the identification and development of beneficial microbes that play a crucial role in fighting infectious diseases and enhancing immune function.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers — 2.5% of this cohort's audience
Funding rounds
- Jul 2025Grant (prize money)$393K
- Oct 2024Seed$1.1M
Founders & team
Investors
Natural Products Canada
#10
Seed · Toronto, Ontario · founded 2017 · 5 employees$1.6Mraised▾
Seed · Toronto, Ontario · founded 2017 · 5 employees
Developer of immunotherapies to treat infectious diseases. The company has developed a patented biologic called LCTG-001 to treat PID such as selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID).
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers — 2.1% of this cohort's audience
Funding rounds
- Feb 2025Grant (prize money)—
- Jan 2025Grant (prize money)$304.6K
- Sep 2022Seed$1.6M
- Sep 2022Grant (prize money)$350K
Founders & team
Investors
1517 Fund, Checkmate Capital, SYNAPSE LIFE SCIENCE CONSORTIUM, Njeda, NIH, NIAID
#11
Series A · Ottawa, Ontario · founded 2018 · 29 employees$11.6Mraised▾
Series A · Ottawa, Ontario · founded 2018 · 29 employees
Developer of viral sensitizer technology therapeutics to treat viral infections. The novel Viral Sensitizer technology consists of a library of small molecules (novel Viral Sensitizers) identified using a high-throughput screening process to target viral infections.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 10k LinkedIn followers — 15.8% of this cohort's audience
Activity: 1 product launches · 1 partnerships (incl. Massachusetts Institute of Technology, Landmark Bio, and MilliporeSigma) announced in 12 mo
Funding rounds
- Apr 2024Series A$60K
- Jan 2024Series A$3M
- Apr 2023Grant (prize money)$790K
- May 2022Series A$5M
Founders & team
Investors
Dynamk Capital, Ontario Canada, Innovation, Science and Economic Development Canada, Invest Ottawa, AyaWas Group, Capital Angels Network
#12
Public · Montreal, Montreal · founded 2009 · 46 employees$28.2Mraised▾
Public · Montreal, Montreal · founded 2009 · 46 employees
Developer of antiviral and anticancer drugs. Its lead candidate is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin that is a topoisomerase I inhibitor. It has shown efficacy in preclinical trials against multidrug-resistant breast cancer, small cell lung cancer, uterine cancer, and pancreatic cancer. It is also developing drugs for covid-19.
Funding rounds
- May 2023Post IPO$5M
- Mar 2022Post IPO$19.5M
- Jul 2021Post IPO$900K
- Mar 2021Post IPO$2.1M
Investors
RB Capital Partners
Tech stack
CloudflareCloudflare Browser InsightsCore-JsElementorHello ElementorHttp/3
Funding & investor landscape
$565.2Mtotal disclosed funding
35companies funded
157disclosed rounds
1rounds last 90 days
Most active investors
Gates3 rounds
Notable founders
Eric Marcusson
Co-Founder · Providence Therapeutics
Brad Sorenson
Founder & President & CEO · Providence Therapeutics
Hugh Rogers
CEO · Bionxt
Chris Sinclair
Co-Founder · StokedBio
Jon Stokes
Co-founder and CSO · StokedBio
Harold Wolkin
Chairman · Cytophage
Steven Theriault
Chief Executive Officer · Cytophage
Ashok Masilamani
Chief Technology Officer and Founder · Noze
Michael Glogauer
Co-Founder · Ostia Sciences
Abdelahhad Barbour
Co-Founder & CEO · Ostia Sciences
Viraj Mane
Co-Founder · Lactiga
Jean Diallo
Founder & CEO · Virica Biotech
Prism market signals · Canada · country-scoped Prism corpus, 8,140,565 docs
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · Canada
How research on Diagnostics is moving in Canada
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,270 Canada-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 32% → 58% across 2008–2026.
top research entities
- Ministry of Health175
- University of Toronto136
- McGill University111
- Princess Margaret Cancer Centre84
- University Health Network72
leading researchers
Nitika Pant Pai · Madhukar Pai · Natasha B. Leighl · Rupa Haldavnekar · Krishnan Venkatakrishnan · Bo Tan · Thupten Tsering · Julie Shaw
▲
Breakthroughs210 · 17%
▲ 11%→20% share
▲1.8× share momentum2 median citations66% since 2021mostly methods-led
Breakthroughs are rising (11%→20% of field), led by Liquid biopsy.
rising sub-themes (early→recent)
- Liquid biopsy8→33
- Point-of-care testing14→31
- Cancer2→18
- Biomarker2→17
- Point of care10→22
Newly emergingNucleic acid 0→8 · Coronavirus disease 2019 (COVID-19) 0→8 · Biopsy 0→7
Landmark Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma · 375 cites
◆
Advancements568 · 45%
▲ 43%→45% share
▲1.0× share momentum4 median citations54% since 2021mostly empirical
Advancements are rising (43%→45% of field), led by Liquid biopsy.
rising sub-themes (early→recent)
- Liquid biopsy20→97
- Biopsy5→49
- Point-of-care testing50→71
- Cancer9→28
- Biomarker6→24
Newly emergingSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 0→17 · Coronavirus disease 2019 (COVID-19) 0→12 · DNA methylation 0→8
Landmark Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer · 512 cites
▼
Concerns396 · 31%
▼ 38%→28% share
▼0.7× share momentum8 median citations48% since 2021mostly empirical
Concerns are cooling (38%→28% of field), led by Liquid biopsy.
rising sub-themes (early→recent)
- Liquid biopsy10→41
- Point-of-care testing56→67
- Biopsy5→15
- Point of care21→29
- Asymptomatic3→11
Newly emergingCoronavirus disease 2019 (COVID-19) 0→15 · Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 0→15 · Pandemic 0→8
Landmark Diagnosing COVID-19: The Disease and Tools for Detection · 1,835 cites
RESEARCH HOTSPOTS · Canada
Where diagnostics is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Montreal166 · +0.32
Toronto160 · +0.39
Edmonton/Calgary123 · +0.31
Vancouver84 · +0.35
Waterloo/Hamilton66 · +0.28
Ottawa/Kingston45 · +0.25
PATENT SIGNAL · Canada
Who's filing diagnostics patents in Canada
Canada diagnostics patent filing is cooling — 51 filings from 36 assignees (2016–2025), led by FIO, Invidx, Chromedx; annual filings 4→2.
51 filings36 assigneespeak 11/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- FIO29
- Invidx19
- Chromedx12
- Macleod Jason Andrew7
- Nemeth Attila Csaba7
- Collier Gordon Bruce7
- Dicke William Charles7
- I STAT5
Common questions
How many Infectious Diseases companies are there in Canada?
Radar tracks 85 indexable Infectious Diseases companies headquartered in Canada that meet our profile-completeness bar.
What is the total funding raised by Infectious Diseases companies in Canada?
The Infectious Diseases companies in Canada on this list have raised a combined $565.2M in disclosed equity funding across 35 funded companies.
Which is the highest-funded Infectious Diseases company in Canada?
Methylgene is the highest-funded Infectious Diseases company in Canada, with $61.7M in disclosed equity funding.
How many Infectious Diseases companies in Canada are funded?
35 of the 85 Infectious Diseases companies in Canada on this list have disclosed at least one equity funding round.
How many Infectious Diseases unicorns are there in Canada?
None of the Infectious Diseases companies in Canada on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Canada Infectious Diseases companies?
The most active investors in Canada Infectious Diseases companies on this list include BDC, Gates, TIAP, Beresford Ventures, CTI Life Sciences Fund.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.